- Tytuł:
- A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
- Autorzy:
- Źródło:
- BMC Research Notes. 16(1)
Czasopismo naukowe